[HTML][HTML] Four weeks of treatment with rifaximin fails to significantly alter microbial diversity in rectal samples of HIV-infected immune non-responders (ACTG A5286) …
BB Williams, SJ Green, RJ Bosch, ES Chan… - Pathogens and …, 2019 - ncbi.nlm.nih.gov
Pathogens and Immunity, 2019•ncbi.nlm.nih.gov
Methods: HIV-1-infected individuals receiving ART with CD4-T cell count< 350cells/mm 3
and viral suppression were randomized 2: 1 to rifaximin or no therapy for 4 weeks. Rectal
swabs were collected at baseline (pre-treatment) and at week 4 of rifaximin therapy.
Genomic DNA extracted from rectal swab samples was analyzed using high throughput
sequencing and quantitative PCR of bacterial 16S ribosomal RNA (rRNA) genes. Results:
Forty-eight HIV-infected participants (31 received rifaximin, 17 no treatment) were included …
and viral suppression were randomized 2: 1 to rifaximin or no therapy for 4 weeks. Rectal
swabs were collected at baseline (pre-treatment) and at week 4 of rifaximin therapy.
Genomic DNA extracted from rectal swab samples was analyzed using high throughput
sequencing and quantitative PCR of bacterial 16S ribosomal RNA (rRNA) genes. Results:
Forty-eight HIV-infected participants (31 received rifaximin, 17 no treatment) were included …
Methods:
HIV-1-infected individuals receiving ART with CD4-T cell count< 350cells/mm 3 and viral suppression were randomized 2: 1 to rifaximin or no therapy for 4 weeks. Rectal swabs were collected at baseline (pre-treatment) and at week 4 of rifaximin therapy. Genomic DNA extracted from rectal swab samples was analyzed using high throughput sequencing and quantitative PCR of bacterial 16S ribosomal RNA (rRNA) genes.
Results:
Forty-eight HIV-infected participants (31 received rifaximin, 17 no treatment) were included. There was broad variability in the recovery of bacterial rRNA from the specimens at baseline. No major significant (FDR P< 0.05) effects of rifaximin treatment on alpha-or beta-diversity or individual taxa were observed between or within the treatment arms, with analyses conducted at taxonomic levels from phylum to genus.
Conclusions:
Rifaximin did not meaningfully alter the diversity or composition of the rectal microbiome of HIV-infected individuals after 4 weeks of therapy, although rectal swab specimens varied widely in their microbial load.
ncbi.nlm.nih.gov